Abstract Tamoxifen (Tam) resistance represents a significant clinical problem in estrogen receptor (ER) a-positive breast cancer. We previously showed that decreased expression of Rho guanine nucleotide dissociation inhibitor (Rho GDI) a, a negative regulator of the Rho GTPase pathway, is associated with Tam resistance. We now discover that androgen receptor (AR) is overexpressed in cells with decreased Rho GDIa and seek to determine AR's contribution to resistance. We engineered ERa-positive cell lines with stable knockdown (KD) of Rho GDIa (KD cells). Resistance mechanisms were examined using microarray profiling, protein-interaction studies, growth and reporter gene assays, and Western blot analysis combined with a specific AR antagonist and other signaling inhibitors. Tam-resistant tumors and cell lines with low Rho GDIa levels exhibited upregulated AR expression.
Introduction
Current endocrine therapies, such as Tam and aromatase inhibitors (AIs), are effective at delaying recurrence and increasing overall survival for patients with ERa-positive breast cancer [1] . Despite overall effectiveness, about a third of tumors exhibit de novo resistance to therapy, and about half of patients' tumors will acquire resistance to first-line endocrine therapy [2] . Several mechanisms of Tam resistance (TamR) have been described, including mutation and altered post-translational modifications of ERa, changes in ERa co-activator and co-repressor Electronic supplementary material The online version of this article (doi:10.1007/s10549-015-3609-7) contains supplementary material, which is available to authorized users. expression, and altered expression of cell-cycle regulatory pathway members [3] . Activation of growth factor receptors or altered cytoplasmic signaling has been shown to promote resistance by acting as alternative survival pathways or through bi-directional cross-talk with ERa [3] . Cotargeting these pathways along with endocrine therapy treatment prevents resistance in pre-clinical models but has often failed to achieve the same efficacy in the clinic [4] . Identification of both novel resistance mechanisms as well as biomarkers of response will be required to develop targeted therapy for resistant disease.
We have previously shown that a decrease in expression of a negative regulator of the Rho GTPase pathway, Rho GDIa, leads to TamR associated with Tam agonist activity in ERa-positive breast cancer cells [5] . Known mainly for regulating rearrangement of the actin-cytoskeleton, the Rho GTPases play a role in cell membrane morphology, cell motility, phagocytosis, and formation of secretory vesicles [6] . High expression of Rho GTPases and low expression of Rho GDIs has been observed in breast tumors and is associated with higher grade tumors, local recurrence, and increased metastasis [7] .
We have demonstrated that AR overexpression in ERapositive breast cancer cells also increases Tam agonist activity and resistance to Tam and AI therapy [8, 9] . AR is a nuclear receptor that exerts its effects on cells through both classical genomic mechanisms and rapid non-genomic actions. AR acts as a ligand-dependent transcription factor via a classical genomic mechanism which involves homodimerization and translocation to the nucleus upon binding androgen hormones, binding to specific DNA sequences, and recruiting co-regulators to initiate transcriptional changes over time [10] . AR can also cause rapid initiation of cytoplasmic signaling cascades, including activation of protein kinase A, protein kinase C, and ERK, via a nongenomic mechanism involving binding cytoplasmic and membrane-bound proteins, such as c-Src [10] . AR is expressed in approximately 80 % of breast tumors and is co-expressed with ERa in about 65 % of tumors [11] . Clinically, a high AR to ERa expression ratio in primary breast tumors is associated with failure of Tam treatment within 5 years and decreased disease-free survival during Tam treatment [12] . Higher AR activity has also been found in tumors that recur following AI therapy [13] .
In this study, we report that decreased Rho GDIa expression in ERa-positive breast cancer cells is associated with overexpression of both AR and EGFR. In these cells, we observe a novel mechanism of enhanced Tam agonist activity through AR-mediated activation of EGFR signaling to ERa. AR and EGFR inhibitors restored Tam sensitivity, suggesting that targeting of both AR and EGFR may be effective in resistant cells with low Rho GDIa expression.
Results

Low levels of Rho GDIa are associated with AR overexpression and activation of the EGFR/MAPK/ ERK signaling pathway in TamR cells
To discover novel pathways involved in the development of TamR, we analyzed differential gene expression in Tamresistant ERa-positive metastatic tumors using microarray [14] . Expression in five metastatic tumors from Tam treated patients who had a recurrence while on therapy (within 2 years) was compared to four primary tumors from patients treated with Tam who did not have a recurrence during follow up. Rho GDIa was expressed at lower levels in the resistant tumors from this cohort [5] . We developed a cell line model of these tumors by stable knockdown of Rho GDIa in MCF-7 breast cancer cells using specific shRNAs (KD cells); Tam acted as an agonist by increasing ERa transcriptional activity in this model [5] . We described a novel mechanism of resistance in which Rho GTPase pathway activation resulted in ligand-independent activation of ERa in these cells. AR was also overexpressed in a subset of the metastatic, resistant tumors with low Rho GDIa expression (Fig. 1a, b) . Concomitant with Rho GDIa knockdown, endogenous levels of AR protein and mRNA were elevated in the MCF-7 KD cell line model of these tumors when compared to control cells expressing an empty vector plasmid (Vec cells) (Fig. 1c, d ). Endogenous levels of AR were elevated in an additional knockdown model engineered using ZR-75-B cells with stable lentiviral Rho GDIa shRNA. We have previously demonstrated that AR overexpression can increase Tam agonist activity and promote endocrine therapy resistance in ERa-positive breast cancer cells [8] . These observations imply that a reduction in Rho GDIa expression leads to increased expression of AR, a protein shown to increase Tam agonist activity and resistance.
Activation of growth factor and cytoplasmic signaling pathways, especially the ErbB receptor family and the MAPK/ERK kinases, has been associated with TamR [15] [16] [17] . To determine if these pathways are activated in response to Tam in our models, we treated ZR-75-B Vec and KD cells with Tam for 24 h and performed microarray analysis. Our analysis identified 1,040 probes differentially expressed ([1.5 fold) in the KD cells with Tam treatment  (Supplementary Table 1) , and we performed gene set enrichment analysis utilizing these genes. There was significant (p \ 0.001) overlap with four oncogenic signatures in the MSigDB database (http://www.broadinstitute.org/ gsea/msigdb). Sixty of the differentially expressed genes matched genes increased in expression and 58 matched genes decreased in expression with EGFR pathway activation ( Table 1 ). In addition, 60 differentially expressed genes matched genes whose expression increased and 68 matched genes whose expression decreased with MEK1 activation. This suggests that activated EGFR and MEK1 are associated with the Tam-resistant phenotype observed with Rho GDIa knockdown.
Since we observed signatures of EGFR and MEK1 activation, we wanted to determine if EGFR and MEK1 expression was altered in our models. EGFR RNA levels were found to be increased 1.8-fold in the ZR-75-B KD cells following Tam treatment by microarray analysis (Table 2) . Basal EGFR protein levels were elevated in both the ZR-75-B and MCF-7 KD cell line models (Fig. 1c) . We also performed a reverse phase protein array (RPPA) and found increased MEK1 protein expression in the KD cells following Tam treatment (Fig. 1e, f) . We conclude that a decrease in Rho GDIa expression leads to increased EGFR and MEK1 expression that may also be associated with Tam agonist activity.
Since we previously observed that Tam increased ERa transcriptional activity in the MCF-7 KD cells [5] , we examined the microarray data for evidence of ERa transcriptional activation in the ZR-75-B KD model. The hallmark gene sets of the MSigDB database contain welldefined signatures of cellular processes developed by combining coordinate expression data from multiple related studies. We found significant (p \ 0.001) overlap, with 
AR interacts with EGFR and promotes activation of downstream pathway members
It has been shown that AR expression promotes EGFR activation via non-genomic mechanisms, which involve protein complex formation between EGFR and AR [18] . AR non-genomic activity also enhances phosphorylation of EGFR and its downstream targets ERK1/2 in breast and prostate cancer cells [18] [19] [20] . We previously observed a constitutive increase in ERK1/2 phosphorylation in MCF-7 KD cells [5] , so we addressed whether AR may be promoting constitutive activation of EGFR and downstream ERK1/2 in KD cells. Subcellular localization of AR and EGFR in ZR-75-B KD cells was examined by confocal microscopy. Co-localization of AR and EGFR was indicated by co-staining (Fig. 2a) . Since AR and EGFR colocalized, we tested for interaction between the two. Interactions between AR and EGFR were observed with basal conditions using proximity ligation assays (Fig. 2b) . Treatment with Enzalutamide, a third-generation AR antagonist used in the treatment of castration-resistant prostate cancer [21] , decreased these interactions. In addition to interaction with AR, increased constitutive EGFR phosphorylation was seen in ZR-75-B KD cells ( Fig. 3a) , which was blocked by Enzalutamide ( Fig. 3b) . Enhanced constitutive EGFR phosphorylation that was sensitive to AR inhibition was also observed in MCF-7 KD cells ( Supplementary Fig. 1A , B). ZR-75-B KD cells exhibited increased basal ERK1/2 phosphorylation ( Fig. 3c ) that was also inhibited by Enzalutamide (Fig. 3d ).
As expected, the EGFR inhibitor gefitinib also reduced ERK1/2 phosphorylation ( Fig. 3d ), confirming that ERK1/ Selected genes differentially expressed in ZR-75-B KD cells compared to Vec cells. Cells were treated with Tam for 24 h and analyzed using gene expression microarray 2 was a downstream signaling target of EGFR. Enzalutamide and gefitinib treatment attenuated the constitutive ERK1/2 phosphorylation in MCF-7 KD cells as well ( Supplementary Fig. 1C , D). We conclude that AR forms a complex with EGFR in the KD cells, resulting in enhanced EGFR activation and downstream signaling to ERK1/2. Activation of HER receptor family members, including EGFR, is a common mechanism of escape from Tam inhibition in ERa-positive cells [22, 23] . Our microarray results indicated that EGFR and downstream ERK activation were associated with Tam treatment, so we determined if Tam treatment altered phosphorylation of these proteins in our cells. EGFR and downstream ERK1/2 phosphorylation was increased by Tam in ZR-75-B KD cells compared to control conditions (Fig. 3e, f) . Tam also induced phosphorylation of both proteins in MCF-7 KD cells ( Supplementary Fig. 1E, F) . Since AR promotes constitutive activation of EGFR in our cells we next asked if it also contributed to Tam-induced EGFR activation. Tam-stimulated phosphorylation of EGFR and downstream ERK1/2 was blocked by Enzalutamide and gefitinib (Fig. 3e, f) . AR and EGFR inhibitors had similar effects in MCF-7 KD cells ( Supplementary Fig. 1E, F) . We conclude that AR enhances the activation of EGFR in response to Tam treatment, and conclude that this activation is a potential mechanism of resistance in our models.
AR and EGFR promote ERa activation and Tam agonist activity
ERa is phosphorylated at serine (Ser) 118 by ERK1/2 resulting in ligand-independent activation [24, 25] . Enhanced constitutive Ser118 phosphorylation was previously observed in MCF-7 Rho GDIa KD cells [5] . AR causes ERK1/2 activation through EGFR in these cells, so we asked whether this results in ERa phosphorylation at Ser118 and subsequent activation. Ser118 phosphorylation was constitutively elevated in ZR-75-B KD cells (Fig. 4a) . EGF treatment stimulated Ser118 phosphorylation (Fig. 4a ). Enzalutamide and gefitinib reduced Ser118 phosphorylation levels in both ZR-75-B and MCF-7 KD (Fig. 4a, Supplementary Fig. 2A ). To examine the effect of AR on ERa transcriptional activity, we treated our model cells with R1881, a potent synthetic ligand for AR that is non-aromatizable. R1881 increased AR and ERa transcriptional activities by 1.4-fold and 3.0-fold, respectively, in ZR-75-B KD cells (Fig. 4b, c) . Treatment produced a 1.6-fold increase in AR activity and a 2.8-fold enhancement of ERa activity in MCF-7 KD cells ( Supplementary  Fig. 4A, B) . R1881 also increased interactions between AR and EGFR (Sup Fig. 3 ), indicating that ERa activation by R1881 may be due to increased non-genomic signaling of AR to EGFR. A constitutive increase in ERa transcriptional activity was observed in both ZR-75-B and MCF-7 KD cells, which was inhibited by Enzalutamide and gefitinib (Fig. 4d, Supplementary Fig. 4C ). These results demonstrate that AR promotes ERa phosphorylation and activation through EGFR in cells with low Rho GDI expression.
In some cases, Tam treatment can induce Ser118 phosphorylation contributing to ERa activation and resistance [26, 27] . In MCF-7 KD cells, we have previously shown that Tam acts as an agonist, stimulating ERa activity in MCF-7 KD cells [8] . Tam treatment enhanced Ser118 phosphorylation and increased ERa activation in ZR-75-B as well as MCF-7 KD cells, suggesting that Tam agonist activity was due to induction of Ser118 phosphorylation (Fig. 4e, f, Supplementary Figs. 2B, 4D ). Since AR promoted constitutive Ser118 phosphorylation and activation of ERa in our models, we next asked whether Tam-induced ERa activation is through AR. Enzalutamide and gefitinib blocked Tam-induced ERa phosphorylation and Tam agonist activity in ZR-75-B KD cells (Fig. 4e, f) . Similar results were observed in MCF-7 KD cells (Supplementary Figs. 2B, 4D). We conclude that Tam agonist activity in the KD cell lines is due to enhancement of ARmediated signaling via EGFR to ERa Ser118.
AR and EGFR enhance basal and Tam-induced proliferation
Activation of EGFR signaling stimulates proliferation in ERa expressing breast cancer cells [28] [29] [30] . MCF-7 Rho GDIa KD cells exhibit enhanced basal proliferation [5] , so we tested if EGFR activation by AR was playing a role in the constitutive growth that was observed. R1881 treatment increased proliferation 2.8 fold in ZR-75-B KD cells and 1.3 fold MCF-7 KD cells (Fig. 5a ). Constitutive proliferation of ZR-75-B KD cells was reduced to 60 and 40 % of basal levels, respectively, by Enzalutamide and gefitinib treatments (Fig. 5b) . The inhibitors were also able to reduce basal proliferation of MCF-7 KD by 20 % (Fig. 5b) . This suggests that activation of EGFR by AR increases KD cells' proliferative ability.
We have previously shown that Tam exhibited agonist effects on proliferation in MCF-7 KD cells [5] . We wanted to determine if Tam effects on growth were also mediated by AR and EGFR. Tam acted as a growth agonist in both ZR-75-B and MCF-7 KD cells (Fig. 5c) . Enzalutamide blocked Tam-stimulated growth in ZR-75-B KD cells, bringing proliferation to untreated levels (Fig. 5c) . Enzalutamide also attenuated Tam-induced proliferation of MCF-7 KD cells to 70 % of basal levels (Fig. 5c) . Gefitinib blocked Tam agonist growth as well, bringing proliferation to 40 % of untreated levels in ZR-75-B KD cells and to untreated levels in MCF-7 KD cells (Fig. 5c) . We conclude that Tam-resistant growth is due to AR-mediated activation of EGFR in both cell lines with decreased Rho GDIa expression.
Discussion
About half of ERa-positive breast tumors exhibit de novo resistance to endocrine therapies, such as Tam, and approximately a third of the remaining tumors will acquire resistance to first-line therapy [2] . Since 75 % of breast tumors are ERa-positive, resistance to endocrine therapy represents a major clinical problem affecting a significant portion of patients [25] . Signaling activation resulting in alternative survival pathways or activation of ERa through bi-directional cross-talk are common resistance mechanisms [3] . Co-targeting such pathways along with endocrine therapy often restores Tam sensitivity in pre-clinical models, but infrequently in clinical studies, indicating an urgent need for the identification of predictive biomarkers for targeted therapy response [4] . Here we demonstrate that Rho GDIa expression was correlated with expression of key nuclear and growth factor receptor pathways affecting response of breast cancer cells to Tam. We also discovered a new mechanism by which AR acts through non-genomic activation of EGFR signaling to ERa, leading to Tam agonist activity and resistance following a decrease in Rho GDIa expression.
Overexpression of Rho GTPases is common in breast tumors and Rho GTPase overexpression coupled with low expression of Rho GDIs is correlated with higher grade tumors, local recurrence, and increased metastasis [7, 31] . We have previously established that the Rho GTPase pathway is also a central mediator of Tam response. A decrease in Rho GDIa expression and subsequent activation of Rho GTPases conferred resistance via activation of PAK1 and subsequent phosphorylation of ERa at a critical regulatory residue Ser305 [5] . In the current study, we show that a decrease in Rho GDIa expression increased the expression of EGFR, AR, and MEK1, all of which participated in signaling to ERa and TamR. Our work suggests that the Rho family of proteins act as drivers of endocrine therapy resistance both through Rho GTPase signaling indirectly to ERa and via modulation of a key growth factor receptor (EGFR) and nuclear receptor (AR).
An increasing number of clinical and in vitro studies have linked increased AR expression and activity with endocrine therapy resistance [8, 9, 12, 13] . AR is expressed in 80 % of breast tumors, often with ERa [11] , so an understanding of how AR affects therapy response is of interest for a significant clinical population. We have previously demonstrated that activation of IGF-1R signaling through Akt is an escape pathway from AI therapy in ARoverexpressing ERa-positive breast cancer cells [9] . The current work describes a novel role for AR in TamR via its endogenous up-regulation with reduced Rho GDIa expression. In cells with Rho GDIa knockdown, increased constitutive phosphorylation of EGFR and downstream ERK1/2 was blocked by Enzalutamide demonstrating that AR promotes activation of EGFR signaling. Constitutive ERa phosphorylation, activity, and proliferation were blocked by Enzalutamide and gefitinib suggesting that ARmediated activation of EGFR signaling to downstream ERK1/2 and ultimately to ERa increased growth. R1881 increased ERa activity and proliferation confirming the role of AR. The observed effects of R1881 on ERa activity are in contrast to studies showing that androgens and AR can inhibit ERa transcriptional activity and growth in hormone responsive cells [32, 33] . In these studies, AR antagonizes ERa activity at the transcriptional level. The ability of R1881 to increase interactions between AR and EGFR suggests that in our model cells R1881 instead acts to increase ERa activity and proliferation via non-genomic signaling of AR to EGFR. Tam acted as an agonist inducing both ERa transcriptional activity and cellular proliferation. Tam-induced phosphorylation of EGFR, ERK1/2, and ERa was also observed, suggesting that EGFR signaling to downstream ERK1/2 and ultimately to ERa was responsible for this Tam agonist activity. The role of AR and EGFR cooperation in this agonist activity was demonstrated by the ability of AR and EGFR inhibitors to block Tam-induced phosphorylation, ERa activation, and growth.
Our work suggests that blockade of AR in combination with EGFR inhibition would be useful in the Tam-resistant setting. The AR inhibitor utilized in our study, Enzalutamide, is a third-generation AR antagonist with a 5-8 fold higher binding affinity for the receptor that uniquely blocks nuclear transport, as well as binding to ligands, DNA, and co-activators [21] . A phase II clinical trial is ongoing to evaluate the safety of Enzalutamide in combination with the AI exemestane in ERa-positive breast cancer [34] . ARtargeted therapy currently represents a promising avenue for management of resistant disease, and our study supports this avenue of clinical research. The role of AR in breast cancer is multifaceted, as androgens have been shown to both stimulate and inhibit proliferation of cancer cells [11, 23, 35] . AR expression in ERa-positive tumors is associated with indicators of good prognosis, including improved overall survival, lower grade and size of primary tumors, and decreased lymph node involvement [33, 36] . At the same time, a high expression of AR relative to ERa levels is associated with decreased response to endocrine therapy and recurrent lesions after AI therapy exhibit increased AR activity [12, 13] . Given the apparent paradoxical role of AR in ERapositive breast cancer, there is an urgent need to identify biomarkers of when AR may be acting as a driver of proliferation and resistance to endocrine therapy, or a potential tumor suppressor. Pre-clinical studies have shown that cross-talk of EGFR with ERa is a major mechanism of endocrine therapy resistance and made co-targeting the receptor with endocrine therapy an attractive option for management of resistant disease [15] [16] [17] . However, a combined analysis of two phase II clinical trials co-targeting EGFR using gefitinib in combination with Tam or the AI anastrozole indicated benefit only in patients receiving no prior endocrine therapy [37] , and a subsequent phase II trial using the EGFR inhibitor AZD8931 in endocrine therapy naive patients found no significant improvement in progression-free survival [38] . Further evaluation of co-targeting EGFR with endocrine therapy would require biomarkers to determine which patients may best respond. Our work identifies candidate biomarkers for AR-targeted and EGFR-targeted therapy. In our cell line models and Tam-resistant tumors from patients, Rho GDIa loss was associated with AR overexpression. Low Rho GDIa coupled with high AR may be a biomarker of resistance, and this possibility needs to be examined clinically. Rho GDIa silencing increased the expression of EGFR and downstream ERK pathway member MEK1. Resistance was also associated with phosphorylation and activation of EGFR and its downstream target ERK1/2. Since Enzalutamide and gefitinib both reversed resistance in these models, overexpression and phosphorylation of EGFR/ERK pathway members when coupled with AR overexpression may be useful biomarkers worthy of further clinical study as determinants for AR/EGFR-targeted therapy.
Our study has described a novel model of AR-mediated TamR through activation of EGFR signaling to ERa in ERa-positive cells with low expression of Rho GDIa. The association of decreased Rho GDIa expression, AR overexpression, and increased expression and activation of EGFR pathway members with resistance could potentially identify patients who would benefit from AR-targeted and EGFR-targeted therapy in future clinical studies.
Materials and methods
Cell culture
All cell lines were maintained at 37°C in a 5 % CO 2 environment. MCF-7 cells were grown in Eagle's Minimum Essential Media (EMEM) (Lonza, Allendale, NJ) and supplemented with 10lg/ml insulin, 200lg/ml penicillin, 200lg/ml streptomycin, 10 % fetal bovine serum (FBS) (Gemini Bio-Products, West Sacrament, CA), and 0.1 mM non-essential amino acids (NEAA). ZR-75-B cells were grown in RPMI 1640 Media (Lonza, Allendale, NJ) supplemented with 200lg/ml penicillin, 200lg/ml streptomycin, 10 % fetal bovine serum (FBS) (Gemini BioProducts, West Sacrament, CA), and 0.1 mM non-essential amino acids (NEAA).
Antibodies, agonists, and inhibitors
Tamoxifen was purchased from Sigma-Aldrich (St. Louis, MO). Enzalutamide and gefitinib were obtained from Selleckchem (Houston, TX). Methyltrienolone (R1881) was obtained from Sigma (St. Louis, MO). For immunoblot assays, AR, total and phosphorylated EGFR (Tyr 845), and phosphorylated ERa (Ser118) antibodies were purchased from Cell Signaling Technology (Beverly, MA). The antibody to total ERa (6F11) was purchased from Vector Laboratories (Burlingame, CA). Antibodies to GAPDH and Rho GDIa were purchased from Santa Cruz Biotechnology (Dallas, TX). Horseradish peroxidase-linked mouse and rabbit secondary antibodies were purchased from GE Healthcare (Piscataway, NJ). For immunofluorescence experiments AR (441) antibody was purchased from Dako (Carpinteria, CA) and EGFR XP Ò antibody was purchased from Cell Signaling Technology (Beverly, MA). Alexa Flour 546-conjugated goat-anti-mouse and Alexa Flour 647-conjugated goat-anti-rabbit secondary antibodies were purchased from Life Technologies, Carlsbad, CA.
Stable transduction
Cell lines with stable Rho GDIa silencing were engineered by viral transduction of a pGIPZ lentiviral plasmid containing a Rho GDIa shRNA expression sequence (GE Dharmacon, Lafayette, CO) and control cells lines by transfection with an ''empty'' pGIPZ containing no shRNA expression sequence. Lentiviral particles were generated using the Trans-Lentiviral Packaging System (GE Dharmacon, Lafayette, CO) as per manufacturer instructions. Cell lines were incubated with viral particles in serum-free growth media overnight to transduce cell lines. Stable transductants were selected for with media containing 1 lg/ml puromycin for 2 weeks and were confirmed by Western blot analysis of RhoGDIa expression.
Anchorage-independent growth assays
In a 24 well plate, 2500 cells per well, were plated in 1 ml of a 0.35 % solution of low-melting point agarose (SeaPlaque Agarose, Lonza Allendale, NJ) in phenol red-free media (EMEM for MCF-7 and RPMI for ZR-75-B) (Lonza, Allendale, NJ) supplemented with 5 % charcoal-stripped FBS (J R Scientific, Inc., Woodland, CA). The cell layer was plated on top of a 350 ll 0.7 % low-melting point agarose base prepared in the same media as the cell layer. Cells were incubated at 37°C for 48 h after plating to allow initial formation of colonies. Indicated treatments diluted in 1 ml of the same media used to plate the assay were then added to the top of well. Media containing treatments was replaced every 4 days. At indicated time points colonies were counted using a GelCount TM scanner unit with provided software (Oxford Optronix, Abingdon, Oxfordshire, United Kingdom).
qRT-PCR
Total RNA was extracted from cells using the RNeasy micro kit (Qiagen, Valencia, CA) according to manufacturer's protocol. First-strand cDNA synthesis was carried out using the SuperScript III Reverse Transcriptase kit (Life Technologies, Carlsbad, CA). cDNAs were amplified and detected using a SYBR Green PCR Master Mix (Life Technologies, Carlsbad, CA) and a 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). Relative gene expression levels were calculated using the DDCt method with normalization to a reference gene (GAPDH). Primers for cDNA amplification were as follows: GAPDH (forward 
Protein extraction and immunoblot
Cells were washed with cold PBS prior to lysing with RIPA buffer. Lysates were then clarified by centrifugation for 10 min at 4°C at 20,0009g. Protein concentrations were determined using a BCA protein assay reagent kit (Pierce, Rockford, IL). Equal amounts of protein were loaded to a 10 % SDS-PAGE gel for resolving. Proteins were then transferred to a nitrocellulose membrane (GE Healthcare, Piscataway, NJ). The membrane was then blocked in 5 % BSA for 1 h at room temperature, incubated with primary antibody (diluted in 5 % BSA) overnight at 4°C, and lastly incubated with secondary antibodies (diluted in 5 % milk) for 1 h at room temperature. Membranes were visualized by addition of enhanced chemiluminescence reagent (Protein Simple, San Jose, CA).
Reporter gene assays
Following starvation for 48 h in phenol red-free media (EMEM for MCF-7 and RPMI for ZR-75-B) (Lonza, Allendale, NJ) supplemented with 5 % charcoal-stripped FBS (J R Scientific, Inc., Woodland, CA), 30,000 cells per well were plated in 24 well plates. Cells were transfected with 0.25 lg/well of luciferase reporter plasmid containing either an estrogen response element (ERE) or an androgen response element (ARE) in the promoter and 0.1 lg/well of a b-galactosidase expressing plasmid. Cells were treated as indicated following transfection. Transfection and luciferase assay were performed as described in [9] .
Immunofluorescence 15,000 cells per well were plated in an 8-well chamber slide in phenol red-containing media (EMEM for MCF-7 and RPMI for ZR-75-B) supplemented with 10 % FBS and incubated at 37°C for 48 h to allow attachment. The media were then changed to phenol red-free media (EMEM for MCF-7 and RPMI for ZR-75-B) supplemented with 5 % charcoal-stripped FBS for starvation for 48 h and incubated with treatments for indicated times. Fixation, permeabilization, blocking, antibody incubation, and microscopy were carried out as described in [9] . Nuclei were stained using Vectashield Ò mounting media with DAPI purchased from Vector Laboratories (Burlingame, CA). All antibodies were used at a dilution of 1:100.
Proximity ligation assay (PLA)
15,000 cells per well were plated in an 8-well chamber slide in phenol red-containing media (EMEM for MCF-7 and RPMI for ZR-75-B) supplemented with 10 % FBS and incubated at 37°C for 48 h to allow attachment. The media were then changed to phenol red-free media (EMEM for MCF-7 and RPMI for ZR-75-B) supplemented with 5 % charcoal-stripped FBS for starvation for 48 h. Cells were then incubated with treatments for indicated times before carrying out the PLA assay as described in [9] .
Microarray
Microarray analysis of patient tumors has been previously described [14] . For cell line studies, 1,000,000 cells were plated in a 10 cm 3 tissue culture dish and incubated overnight at 37°C to allow attachment. Cells then underwent starvation for 48 h in phenol red-free media (EMEM for MCF-7 and RPMI for ZR-75-B) (Lonza, Allendale, NJ) supplemented with 5 % charcoal-stripped FBS. Following starvation cells were treated with vehicle control or 100 nM Tamoxifen for 24 h, RNA extraction, cDNA preparation, and microarray were carried out as described in [9] .
Statistical analysis
Statistical analysis of microarray data was performed using Partek Genomics Suite software (http://www.partek.com/). Expressions were estimated using the RMA (Robust Multichip Average) method. ANOVA (Analysis of Variance) with contrasts was used to find differentially expressed genes and estimated FDR (False Discovery Rate) was determined using the Benjamini and Hocgberg method to correct p-values for multiple comparisons. Data for all other assays were tested for significance using a student's t test (two-sided) with the p value adjusted for multiple comparisons using the Holm method.
